|
|
|
|
||
Re: Going forward...Yes, and my response to him was: @RNAiAnalyst I disagree. They modified TKM-PLK1 P1 to study viral parameters in HBV+ HCC patients. http://globenewswire.com/news-release/2015/08/05/758261/10144708/en/Arbutus-Biopharma-Announces-Second-Quarter-2015-Financial-Results.html … So, as you can see, it DOES make sense to lump this in with ABUS. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
30927 | Re: Going forward... | egomaniakos | 1 | 8/26/2015 5:05:40 PM |